Ordering Paxlovid and Lagevrio
Paxlovid and Lagevrio are available for purchase via the commercial market as of November 1, 2023. As part of the transition of COVID-19 therapeutics distribution to the commercial marketplace, ASPR has implemented the following protocols in accordance with its
Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program:
- Lagevrio ordering through the USG stopped on
November 10, 2023.
- Paxlovid ordering through the USG stopped on December 15, 2023.
For more information about ordering, reporting, and using your supplies, please visit:
Federal Entities
Federal entities may continue to order Paxlovid from the U.S. government (USG) supply. Federal entities, excluding the Department of Defense and Veterans Affairs, may continue to order Lagevrio until supply is depleted. Ordering occurs through Health Partner Ordering Portal (HPOP).
State and Territory Officials
Jurisdictions and other partners should work with their providers/sites to deplete the USG supply in the field and replace inventory with commercial supply as needed.
Reporting Administration of Paxlovid and Lagevrio
The federal government tracks the amount of COVID-19 therapeutic products ordered and administered through the
HPOP portal, monitoring product availability and administration of the USG-distributed products for each state or territory.
All disposal and returns of the USG-procured products need to be recorded in
HPOP.
COVID-19 Therapeutics Summary: USG Supplied Therapeutics Available for Patient Use1
December 17, 2021–September 30, 2024
| Therapeutic |
Delivered |
Administered |
| Paxlovid2 |
19,159,460
|
13,661,261
|
Lagevrio
|
3,486,840
|
1,982,784
|
Total:
|
22,646,300 |
15,644,045 |
1 States, territories, and federal entities, including HRSA
2 Includes EUA Paxlovid and EUA Renal Paxlovid for all central partners and NDA-labeled Paxlovid and NDA-labeled Renal Paxlovid ordered by Federal Entities.
-
Data Source: Tiberius, Updated 09/30/2024 as of 1:00p EST
-
Data through Sunday, 09/29/2024
COVID-19 Therapeutics Summary: Previous USG Supplied Therapeutics No Longer in Use
2020 – 2023
Therapeutics
(currently not in use*) |
Date of
First Issue |
Date of
Last Distribution |
Courses
Delivered |
Courses
Administered |
| Evusheld (300mg doses) |
December 8, 2021 |
January 26, 2023 |
1,032,156 |
738,936 |
| Bebtelovimab |
February 11, 2022 |
November 30, 2022 |
739,889 |
624,633 |
| Sotrovimab |
May 26, 2021 |
April 5, 2022 |
706,692 |
302,209 |
| Bamlanivimab/Etesevimab |
February 9, 2021 |
January 24, 2022 |
642,125 |
610,753 |
| REGEN-COV |
November 21, 2020 |
January 24, 2022 |
2,878,138 |
2,078,587 |
| Bamlanivimab** |
November 9, 2020 |
March 2, 2021 |
664,691 |
N.A. |
*Products are not currently authorized for use in any U.S region due to high frequency of SARS-CoV-2 subvariants to which these therapeutics are unlikely to be effective.
**EUA was revoked for bamlanivimab when administered alone; courses administered data are not available at this time.
Prior COVID-19 Therapeutic Product Efforts
| Date Range |
Threshold/Distribution/Allocation by Jurisdiction |
February 2024-June2024
|
Administered Amounts by Jurisdiction
|
September 2022-December 2023
|
Cumulative COVID-19 Therapeutics Delivered and Administered Amounts by Jurisdiction
|
April 25, 2022 - November 26, 2023
|
COVID-19 Therapeutics Threshold Determinations
|
| September 13, 2021 - April 24, 2022 |
COVID-19 Therapeutics Distribution |
| November 9, 2020 - March 2, 2021 |
Bamlanivimab Distribution |
| November 24, 2020 - February 2, 2021 |
REGEN-COV Distribution |
| July 6, 2020 - October 4, 2020 |
Allocation of Commercial Veklury (Remdesivir) (PDF) |
May 4, 2020 - June 29, 2020
|
Allocation of Donated Veklury (Remdesivir) |
